Hurt 2003.

Methods	BUPROPION Randomized controlled trial Setting: multi‐centre 14 North Central Cancer Treatment Group sites, USA Recruitment: community volunteers.
Participants	578 smokers recruited to first stage of study: >= 15 CPD; 57% F, av age 42, 21% history of MDD 176 smokers abstinent after 8w nicotine patch treatment randomized to relapse prevention intervention 194 non‐abstinent smokers randomized to bupropion as second line therapy
Interventions	(All participants first received nicotine patch for 8w, dose based on cig consumption) Relapse prevention arm: 1. Bupropion for 26w 2. Placebo Second line therapy arm: 1. Bupropion for 8w 2. Placebo
Outcomes	Relapse prevention arm: Abstinence at 12m, (PP, 6m after end of therapy). Second line therapy arm: Abstinence at 6m (4m after end of therapy) Validation: CO < 8 ppm
Notes	Does not contribute to primary analysis. Long‐term follow up for 2nd line Rx arm from authors. Funding: National Cancer Institute, Public Health Service. Medication provided by Glaxo Wellcome and Elan Pharmaceutical.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomized using 'dynamic allocation'.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	"Double‐blind," no further information provided
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Number of participants lost to follow‐up not given. Patients lost to follow‐up considered to be smoking.